Please login to the form below

Not currently logged in
Email:
Password:

William Humphries joins board of Clearside Biomedical

New CEO of Merz Pharma’s US operations joins the eyecare firm's board

Clearside Biomedical has appointed CEO of Merz Pharma's North American operations, William Humphries, to its board of directors.

Humphries joins the US-based firm, which specialises in developing eyecare products, just two weeks after his appointment at Merz Inc.

Clearside will be keen to make use of Humphries' 25 years' experience in the pharma industry as it looks to develop its microinjection platform to develop therapeutics for sight threatening conditions such as macular oedema and vascular leakage.

Prior to his appointment at Merz, Humphries was president of the GlaxoSmithKline company Stiefel, which specialises in dermatology.

Humphries has also held senior executive roles at Allergan, including VP of its US skincare business.

"Having served under Bill at Stiefel, I know firsthand how talented he is in the global commercialisation of products in today's healthcare environment and his experience is already providing an important impact to Clearside Biomedical," said Daniel White, Clearside's president and CEO.

"Bill brings a complementary vision to our company and a wealth of knowledge to the table that will help guide our company to achieving its goal of providing valuable medical solutions for patients suffering from sight-threatening illness."

4th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics